Generic Name: Empagliflozin
Brands: Jardiance
Class: Sodium-glucose cotransporter 2 (SGLT2) inhibitors
Availability: Prescription only (currently in the United States, no generic version is available)
Molecular Formula: C23H27ClO7
Substance UNII: HDC1R2M35U
What is Jardiance?
Jardiance is a sodium-glucose cotransporter 2 (SGLT2) inhibitor. It is the brand name of the drug empagliflozin.
What is Jardiance Used For?
Jardiance is used for the treatment of diabetes. It was approved by the U.S. Food and Drug Administration (FDA) in 2014.
According to the U.S. National Library of Medicine, Jardiance can also help lower the risk of heart attack, stroke, and death in people with type 2 diabetes who also have heart and blood vessel diseases.
How Does Jardiance Work?
Jardiance helps lower blood sugar in people with type 2 diabetes. It’s meant to be used along with diet and exercise. It works by helping the kidneys send excess sugar out of the body through the urine.
How Long Does it Take for Jardiance to Work?
Jardiance may start to help lower blood sugar levels within 1 to 2 weeks. But studies suggest it may take up to 24 weeks for a person to get the full benefits of Jardiance.
Do Not Use Jardiance If:
There are several situations where this medication may not be the right choice for you. According to the FDA, the following should not use Jardiance:
- People with type 1 diabetes
- People with allergies or sensitivities to ingredients in Jardiance
- People with severe or end-stage kidney disease, including people who are on dialysis
- People with diabetic ketoacidosis (a serious health condition that can occur if high blood sugar is left untreated)
Please note that this list may not be complete, and there may be other situations where the use of this drug is not advisable.
Disclaimer: this article does not constitute or replace medical advice. If you have an emergency or a serious medical question, please contact a medical professional or call 911 immediately. To see our full medical disclaimer, visit our Terms of Use page.